The nature of vascular permeability factor (VPF) activity derived from serum-free conditioned medium containing cultured human malignant glial tumors has been further investigated. A 1000-fold purification was accomplished by sequential heparin-Sepharose affinity chromatography and high-performance liquid chromatography gel filtration chromatography steps. Vascular permeability factor activity fails into a molecular weight range of 41,000 to 56,000 D. Activity is bound to hydroxylapatite, carboxymethyl-Sepharose, phenylSepharose, and heparin-Sepharose, whereas little or no activity was bound to diethylaminoethyl-Sephacel. Vascular permeability factor activity is trypsin-and pepsin-sensitive but is unaffected by treatment with ribonuclease A. This suggests that VPF is a hydrophobic, positively charged (cationic) polypeptide with a potentially biologically significant affinity for heparin. As most proteins are negatively charged (anionic) and have no affinity for heparin, a significant advantage was gained by performing these purification steps.
p RIOR reports have described the increased permeability that is characteristic of the microvasculature within primary and metastatic malignant tumors, as well as certain benign brain tumors. ~2,~5. 25 The cerebral edema associated with them is frequently as culpable for the associated symptoms as the primary neoplastic growth. The focus of early studies was primarily concerned with the morphology of cerebral edema and the vascular ultrastructure of tumor-associated and peritumoral vessels, s-~7 ~9 Vasogenic cerebral edema was characterized by infiltration of the white matter interstitial spaces by an ultrafiltrate of plasma. Several features of tumor-associated vascular endothelium, such as widened intercellular junctions, discontinuous tight junctions, membranous fenestrations, noncontiguous basement membranes, active micropinocytosis, and paucity of mitochondria, sharply contrasted with the normal architecture of the bloodbrain barrier (MW Brightman, TS Reese, unpublished data). 6"22 Since many of these features are similar to typ-ical peripheral vasculature (not involving the bloodbrain barrier), it appears unlikely that they solely account for the abnormal permeability of brain tumor vessels.
Several biochemical mediators and nonspecific tumor secretory products have been implicated in the pathogenesis of brain edema. 2 Histamine, serotonin, glutamic acid, polyamines, leukokinins, lymphokines, and products of the kallikrein-kinin, clotting, and arachidonic acid cascades are potent inducers of microvascular permeability associated with allergic, traumatic, ischemic, infectious, and inflammatory conditions. 3.8-io,27.32 Our previous chemical and physical characterization of vascular permeability factor (VPF) from cultured malignant brain tumors readily distinguish brain tumor-derived VPF from these agents. Vascular permeability factor is trypsin-and pepsin-sensitive and its expression is blocked by cycloheximide. Expression of this protein in tissue culture medium in vitro and its activity at the microvascular level in vivo is also inhibited by dexamethasone. Furthermore, it was shown that neither systemic pretreatment of test animals with antihistamines (diphenhydramine, pyrilamine, and cimetidine) and an inhibitor of cyclo-oxygenase (indomethacin) nor intradermal coinjection of these substances with VPF attenuates its activity in vivo.
In the studies described here, a variety of physical and pharmacological manipulations have been performed in order to better define the pathway through which VPF exerts its effect. The previous observation that VPF demonstrated an affinity for immobilized heparin was also investigated in order to gain a purification advantage. Of considerable interest is the observation that both heparin and protamine inhibited VPF activity in vivo when given systemically or as a coinjection with conditioned medium. The studies have shown that blockade of specific cell-surface binding sites, such as heparin and ganglioside moieties, attenuated VPF activity. Furthermore, it was determined that dexamethasone-induced inhibition of VPF expression by cultured malignant glial cells is not due to a reduction in cell viability, cell number, or cellular protein synthesis. Finally, the observation that actinomycin D partially blocks dexamethasone-induced inhibition of VPF activity in vivo supports a mechanism involving induction of de novo protein synthesis as a mechanism of the steroid effect upon VPF activity.
Materials and Methods

Tissue Culture Techniques
Cells derived from tissue explants of human malignant gliomas were cultured at 37"C in 95% air/5% CO2 and 100% humidity in Dulbecco's modified Eagle's medium (DMEM) supplemented with 4 mM L-Nut,amine, 1% penicillin (10,000 U/ml), 1% streptomycin (10,000 t,g/ml), and 10% fetal calf serum. Confluent cultures grown in Falcon tissue culture flasks (175 sq cm growth area) were washed three times with Hanks' balanced salt solution without calcium, magnesium, and phenol red* and incubated with 25 ml of serumfree DMEM for 24 hours. The washing process was then repeated; conditioned serum-free DMEM was collected 5 to 7 days later and concentrated 20-to 40-fold by wet tubing dialysist against 0.05-M ammonium bicarbonate titrated to pH 7.4 with glacial acetic acid followed by shell freezing in super-cooled acetone and lyophilization for 48 hours. The lyophilized product was then reconstituted using Dulbecco's phosphatebuffered saline (DPBS) without calcium or magnesium~c and filtered through a 0.45-~ membranew prior to assay for VPF activity or biochemical characterization steps.
Flasks of confluent cells were subcultured, using standard trypsinization procedures, every 5 to 20 days as necessitated by biological growth patterns. Confluent cultures contained 6 to 8 x 10 7 cells with viability greater than 95% as confirmed by the trypan blue dyeexclusion method. The glial origin of our stock cultures has been confirmed by their staining of glial fibrillary acidic protein. Stock cultures were periodically monitored for Mycoplasma infection.
Miles Microvascular Permeability Assay
The Miles assay 21 is a biological assay of induction of capillary permeability in normal skin following the intradermal injection of test substances. A modification of the original assay described previously for brain tumor-derived VPF activity 7 was used. For this study, 450 to 500 gm male Hartley-strain guinea pigsll were shaved and anesthetized with diethyl ether, the animals received an intracardiac injection of 1% Evans blue dye and 10 uCi (2.22 x 10 7 disintegrations per minute, dpm) of iodine-125-labeled bovine serum albumin (125I-BSA, specific activity 2.0 uCi/ug)** in a total volume of 1.0 ml via a No. 25 and the injection sites were excised and counted to measure ~25I-BSA extravasation. The previous practice of drying and weighing individual injection sites has been abandoned. Instead, the small areas of dye extravasation produced by the lessened injection volumes (50 vs. 100 ul) were consistently encompassed and excised by means of a 5-mm circular leather-punch. This method produces skin tags of constant surface area and weight, thereby eliminating the need for drying and weighing. The VPF activity contained within injection sites is quantified directly with a Beckman Gamma 4000 counter~ and is expressed as dpm.
Binding of VPF activity to Affinity and 1on-Exchange Resins
A series of columns containing 1.0 ml bed volumes of hydroxylapatite, heparin-Sepharose (CL-6B), carboxymethyl-Sepharose (C-50), diethylaminoethyl-Sephacel (A-50), and phenyl-Sepharose (CL-4B) resins were cycled according to the manufacturer's instructions and equilibrated with DPBS.w A solution of concentrated conditioned medium was prepared by adding 45 mg lyophilized powder (90% to 95 % protein by the method of Lowry, et al. z~ to 30 ml DPBS. This stock VPFsolution was then titrated to pH 7.4, and 2.0 ml (approximately 3.0 mg protein) was added to each of the columns after equilibration by rocking for 60 minutes. Miles and Lowry assays 2~ were performed on the flowthrough products to determine whether there was a differential binding of VPF activity and other proteins to the various resins under these conditions.
Heparin-Sepharose Affinity Chromatography
It has previously been determined that VPF binds immobilized heparin and that activity is eluted by increasing ionic strength using NaC1. To more precisely determine the optimal elution conditions, a heparinSepharose (CL-6B) column was used employing a 320-ml bed volume. As a preparative step, 300 mg of lyophilized conditioned medium was bound to herapinSepharose CL-6B in a 0.3 N NaC1/0.01 M sodium phosphate buffer solution (pH 7.4) for 2 hours and rinsed with the same until the eluent had no detectable protein (Bio-Rad method). After the column had been poured, a 600-ml saline gradient (0.3 to 0.8 N NaC1) was used to elute bound proteins at a flow rate of 30 ml/hr (100 x 6 ml fractions). The fractions were spinconcentrated around 0.05-N NaC1 points using Centricon-30 microconcentrators.]l The grouped fractions were rinsed in DPBS then submitted to the Miles assay 2~ and Lowry protein determination. 2~
Gamma counter manufactured by Beckman Instruments, Inc., Fullerton, California.
w Columns obtained from Bio-Rad, Richmond, California; resins obtained from Pharmacia, Inc., Piscataway, New Jersey.
11 Microconcentrators, 30,000 MWCO, manufactured by Amicon Corp., Danvers, Massachusetts.
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High-Performance Liquid Chromatography
High-performance liquid chromatography (HPLC) was performed with a Gilson liquid chromatography system and a Spherogel-TSK-2000 gel filtration sizing column.* The run was controlled by an Apple IIe computer and preprogramed software.t Column effluents were monitored at 280 nm and recorded on a printer. A 250-ul sample of partially purified VPF was injected into the apparatus after it had been calibrated with known molecular weight standards (14.2, 24, 36, 45, and 66 kD). All fractions were then tested for protein and activity content using the assay of Lowry, et al.,2~
the Bio-Rad Laboratory technique, and the assay of Miles and Miles. 2~ Once the fraction containing VPF activity was identified, a graph plotting the fraction number versus the log molecular weight of protein standards was created to determine the approximate molecular weight range that encompassed VPF activity.
Coinjection of Conditioned Medium with Protease Inhibitors
A variety of serum constituents are known to induce vascular extravasation. To determine whether VPF activity was related to serum components such as leukokinins, clotting factor XIIa (Hageman factor), plasmin, or kallikrein, samples of conditioned medium were coinjected intradermally with pepstatin-A (625 ~g/ml), hexadimethrine (50 ug/ml), aprotinin (200 ug/ml), soybean trypsin inhibitor (1000 ug/ml), or phenylmethanesulfonyl fluoride (300 ug/ml). Controls consisted of DPBS alone and protease inhibitor solutions in DPBS.
Coinjection of Conditioned Medium with ReceptorDestroying Enzymes
To determine the importance of endothelial cellsurface binding to VPF activity, a series of enzymes (heparinase, 5 U/ml; neuraminidase, 0.5 U/ml; and Nacetyl-neuraminic acid aldolase, 0.5 U/ml) known to be directed against heparan sulfate and sialic acid moieties were injected intradermally with VPF shortly after preparation of the appropriate solutions. Controls consisted of the enzyme solutions without VPF medium.
Treatment of Conditioned Medium with Other Enzymes
To determine whether VPF was a complex molecule (proteoglycan or lipoprotein) composed of nonprotein components essential to its activity, hyaluronidase (150 to 750 U/ml), chondroitinase-ABC (1.5 U/ml), lipase (100 to 800 U/ml), and ribonuclease-A (180 Kunitz U/ ml) were coinjected with concentrated conditioned * Liquid chromatography system manufactured by Gilson Medical Electronics, Inc., Middleton, Wisconsin; Spherogel-TSK-2000 gel manufactured by Beckman Instruments Inc., San Ramon, California.
t Program obtained from Apple Computer Inc., Cupertino, California; duration 60 minutes, rate 0.5 ml/min, fraction interval 2 minutes; total number 30 fractions. medium after incubation for 60 minutes at 37~ Controis consisted of the enzyme solutions without VPF medium.
Heparin and Protamine Studies
A marked affinity of VPF for immobilized heparin has been reported previously. 7 To determine whether this implicated an interaction between VPF and hepafin-like moieties on endothelial cell surfaces for induction of increased permeability, guinea pigs were pretreated with parenteral heparin sodium (2500 U/kg) or protamine sulfate (20 mg/kg) by intracardiac injection before intradermal injection of VPF medium. Control animals received 0.5 ml of DPBS, and a separate group of test animals received coinjection of conditioned medium with heparin sodium (500 ~g/ml) and protamine sulfate (100 ug/ml).
Cholera Toxin and Human Gamma Interferon Studies
Certain gangliosides have been previously reported to facilitate the activity of tumor angiogenesis factor in vitro.l This was thought to be related to an interaction between tumor angiogenesis factor and ganglioside moieties on endothelial cell surfaces. 11 Cholera toxin (/3-subunit) and, to a lesser degree, human ~, interferon, are known to competitively bind ganglioside residues. To determine whether VPF activity is facilitated by interactions with ganglioside moieties, coinjection of conditioned medium with cholera toxin (B-subunit, 100 fzg/ml) and human 3' interferon (1000 U/ml) was performed; similar injections without VPF-containing medium were made as control studies.
Protein Synthesis Determinations
To further investigate the observation that dexamethasone inhibits expression of VPF by cultured human glioma, U251 cells grown to confluency in DMEM plus 10% fetal calf serum were transferred to serumfree medium containing 10 -~, 10 -9, 10 -7, and 10 -5 M dexamethasone sodium phosphate.~ This medium was not changed again for the duration of the experiment. Conditioned medium was then collected and submitted to the Miles permeability assay 2~ on Days 2, 4, and 7. Parallel cultures grown in 24-well tissue culture platesw were used for cell counts and protein synthesis determinations. At the time of protein synthesis determination, the cells were washed twice in leucine-free DMEM and then incubated to 90 to 120 minutes in leucine-free DMEM containing 2.5 #Ci/ml tritiated (3H)-leucine (specific activity 5 Ci/mM).ll Incorporation was terminated by aspiration of the medium and Dexamethasone obtained from Elkins-Sinn, Inc., Cherry Hill, New Jersey.
w Culture plates manufactured by Costar Plastics, Inc., Cambridge, Massachusetts.
II Prepared DMEM obtained from Dupont-New England Nuclear, Boston, Massachusetts.
washing the cells twice with ice-cold DPBS. After dissolvingthe contents of each well in 0.5 ml of 0.5 N NaOH, a 0,2-ml aliquot was used for Lowry assay 2~ and 0.2 ml was transferred to a centrifuge tube and neutralized with 5 N HC1. This solution was precipitated in icecold 10% trichloroacetic acid and pelleted at 2000 rpm for 10 minutes; the supernatant was discarded. This process was repeated three times, after which the final pellet was dissolved in 0.05 N NaOH, neutralized, and mixed with Hydrofluor, then counted on a scintillation counter.* Protein synthesis is expressed as picomoles (pM) of 3H-leucine incorporation/hr/mg of protein.
Treatment of Test Animals with Actinomycin D
It has previously been shown that pretreatment of male Hartley-strain albino guinea pigs with dexamethasone markedly reduced expression of VPF activity in the Miles assay. 7 This inhibitory effect is thought to be unrelated to nonspecific membrane stabilization as intradermal coinjection of dexamethasone with VPF was shown not to alter activity. Furthermore, significant inhibition of VPF activity does not occur in test animals given dexamethasone less than 1 hour prior to intradermal injections of VPF. To determine whether the action of dexamethasone is mediated by induction of de novo protein synthesis, a series of in vivo studies were performed whereby actinomycin D (1.0 mg/kg) was administered by intracardiac injection to 20 guinea pigs 2 hours prior to subcutaneous delivery of dexamethasone (2.0 mg/kg).
Results
Experiments were designed to determine which affinity and ion-exchange resins would bind VPF activity. Whereas 90% to 95% of sample activity was bound to immobilized heparin (heparin-Sepharose, CL-6B), hydrophobic resin (phenyl-Sepharose, CL-4B), and hydroxylapatite, only 40% to 45% was bound to carboxymethyl-Sepharose (C-50). In contradistinction, only 5 % of sample activity was bound to diethylaminoethylSephacel (A-50) whereas 80% to 85% of sample protein was sequestered by this resin.
Employing a heparin-Sepharose column and NaC1 gradient revealed that peak elution of VPF occurs at a salt concentration of 0.45 N NaC1 and produces a 26-fold increase in sample specific activity. After this partially purified sample was applied to an HPLC sizing column, a molecular weight range of 41,000 to 56,000 D was determined for the activity-containing fraction, and an additional 25-fold increase in specific activity was realized, for a total approximate purification of 1000-fold (Table 1) .
Coinjection of conditioned medium with hexadimethrine, aprotinin, soybean trypsin inhibitor, pepstatin-A, or phenylmethanesulfonyl fluoride did not alter * Hydrofluor obtained from Dupont-New England Nuclear, Boston, Massachusetts; scintillation counter manufactured by Beckman Instruments, Inc., Fullerton, California. :~ Protein for these two steps was undetectable by routine methods. The stated specific activity therefore represents the lowest possible value, as we presumed the protein to be just below the level of detection. It is possible that, in assuming this, we have grossly underestimated the final specific activity and therefore the extent of purification. induction of increased permeability by VPF in vivo as determined by the Miles assay (Table 2 ). This suggests that VPF acts independently of clotting factor XIIa (Hageman factor), plasmin, tissue plasminogen activator (t-PA), kallikrein, leukokinins, and serine esterase (elastase). Similarly, exposure of conditioned medium to ribonuclease-A, chondroitinase-A,B,C, hyaluronidase, and lipase did not inhibit VPF activity, suggesting at least that ribonucleic acid (RNA), glycosaminoglycan, and lipid moieties were not essential components of the molecules' active site.
A well-defined glycocalyx, composed primarily of sulfated glycosaminoglycans, is known to be present on capillary endothelial cell surfaces. Its primary function is thought to be the selective regulation of endothelial cell binding and transcapillary passage of macromolecules, as well as other cell types. This cell coat is largely composed of polyanionic heparan sulfate and sialic acid residues. The cationic nature of the VPF molecule at neutral pH would suggest a likely mechanism for direct endothelial cell-surface binding and interaction. Treatment with the cell-surface receptor-destroying enzymes heparinase, neuraminidase, and N-acetylneuraminic acid aldolase consistently decreased vascular extravasation (Experiments 1 and 2, Table 3 ). Induction of microvascular permeability by VPF was inhibited by pretreating test animals with intracardiac heparin (which binds circulating VPF) or protamine (which competes with VPF for heparin-binding sites on the endothelial cell surface), or by coinjecting conditioned medium with these substances (Experiments 3 and 4, Table 3 ). Furthermore, coinjection of VPF with cholera toxin (/~-subunit) or human ~/ interferon had definite inhibitory effects on permeability induction (Experiments 2 and 5, Table 3 ).
Studies to determine how dexamethasone affects VPF expression by cultured cells failed to reveal a direct toxic effect as measured by cell viability (> 98% by trypan blue exclusion) and final cell counts. Whereas VPF expression was significantly inhibited by the presence of glucocorticoid, we found no evidence of this effect being related to a general inhibition of cellular protein synthesis by steroid (Table 4) . In vivo inhibition of VPF activity by dexamethasone was partially reversed if the test animals were given actinomycin D 2 hours prior to treatment with glucocorticoid (Table 5 ). This suggests that de novo synthesis of a polypeptide intermediate is required in order for the protective effect of dexamethasone to occur.
Discussion
We have previously demonstrated that serum-free conditioned medium derived from cultures of human malignant gliomas contains a substance that increases * Each experiment had a separate negative control study. DPBS = Dulbecco's phosphate-buffered saline; VPF = vascular permeability factor; IzSI-BSA = iodine-125-1abeled bovine serum albumin; IV = intravenous administration. Values are means + standard error of the means.
~" Variability in starting VPF activities relates to sample preparation (that is, the quantity of lyophilized protein added to a volume of DPBS in making up an aliquot for study was random). microvascular permeability after intradermal injection in guinea pigs. Vascular permeability factor activity in tissue culture medium accumulates with increasing time of culture. Cycloheximide or dexamethasone suppress expression of this activity in vitro. The VPF secreted by malignant brain tumors is an acid-stable heat-labile macromolecule that was inactivated by trypsin and pepsin but is unaffected by ribonuclease-A. In addition, polyclonal immunoglobulin G (IgG)~-directed against VPF derived from guinea pig line 10 bile duct carcinoma resulted in complete elimination of brain tumor VPF activity. 7 These features distinguished our factor from highly acid heat-labile prostaglandins and t IgG provided by Beth Israel Hospital, Boston, Massachusetts. tThe mean SEM for vascular permeability factor (VPF) activity counts was determined to be 7.5%. The control VPF activity values (0 dexamethasone) for Days 2, 4, and 7 were 1294, 7677, and 11,555 dpm, respectively.
Cell counts were performed in quadruplicate using a Coulter counter and are expressed as multiples of 105 cells.
w Protein synthesis is expressed as mean picomoles of 3H-leucine incorporation/hr/mg protein • SEM for four samples.
leukotrienes, and were indicative of a polypeptide moiety with significant antigenic similarity across species lines.
We have determined that pretreatment of guinea pigs with systemic dexamethasone prior to intradermal injection of VPF markedly diminishes microvascular permeability. Furthermore, VPF activity was not inhibited by coinjection of VPF with antihistamine (anti-H 1 with or without anti-H2). Intradermal injection of this factor results in a permeability change with a rapid onset at 1 to 5 minutes, a peak at 5 to 15 minutes, reversibility by 20 to 30 minutes, and a characteristic period of desensitization or tachyphylaxis whereby injection of VPF into previously exposed sites results in no further induction of permeability (data not shown). The kinetics of VPF activity, which is similar to those of histamine, bradykinin, prostaglandins, and leukotrienes, indicates a direct action upon capillary endothelium.
Tumor secretion of VPF may contribute to the vasogenic brain edema frequently associated with malignant primary and metastatic intracerebral tumors. The affinity of VPF for immobilized heparin and inhibition of its activity by heparin, protamine, and certain ganglioside blocking agents provide some insight into its mechanism of interaction with the microvasculature. These observations are particularly relevant in light of the ubiquitous presence of both heparin-like and sialic acid moieties on endothelial cell surfaces. A variety of positively charged (cationic) polypeptide products derived from normal and transformed cells have received The binding of brain tumor-derived VPF activity to both carboxymethyl and heparin-Sepharose under physiological conditions is suggestive of a net positive charge. This evidence is further supported by the nearly complete lack of binding to diethylaminoethyl-Sephacel under similar conditions. Furthermore, at physiological pH, VPF activity is more completely bound to immobilized heparin than to carboxymethyl-Sepharose. This suggests a true biological affinity of VPF for heparin, and supports an interactive role with cell-surface heparin moieties. This specific binding is in keeping with the rapid kinetics and biological effects of VPF activity in vivo which are indicative of a direct action upon microvascular endothelial cells. 7
Brain tumor-derived VPF therefore appears to be a cationic polypeptide. This feature distinguishes it from most biological peptides (anionic) and suggests a mode of interaction in common with angiogenic factors. It might also explain our observations that both heparin and protamine are capable of attenuating VPF-induced microvascular protein extravasation in vivo. Of considerable interest are recent reports of the induction of blood-brain barrier disruption by a variety of polycationic substances including poly-L-lysine, hexadimethfine, and protamine sulfate. 29'34'35 The presence of multiple positively charged moieties on these substances was thought to be crucial to interaction with and partial neutralization of the otherwise negatively charged endothelial cell surfaces. As smaller trivalent cations such as ionic lanthanum failed to produce barrier disruption, it was postulated that a critical charge density may be required for endothelial changes to occur. Premixing of protamine with heparin nullified the effect, presumably by the ionic binding of these molecules to each other with subsequent charge neutralization. This interaction is further supported by our observation that coinjection of conditioned medium with heparinase also resulted in a significant attenuation of VPF activity. Similar biologically important interactions have been reported to occur between angiogenesis factors, fibronectins, and endothelial cell-surface ganglioside residues.l Our studies have also suggested that VPF activity is inhibited when cell-surface ganglioside (sialic acid) residues are destroyed by enzymes (neuraminidase and N-acetylneuraminic acid aldolase) or blocked by the #-subunit of cholera toxin. Retention of activity after exposure to ribonuclease-A, chondroitinase-A,B,C, hyaluronidase, and lipase does not entirely rule out VPF being a ribonucleoprotein, lipoprotein, or mucopolysaccharide. However, it does suggest, together with trypsin and pepsin degradation studies, that the active site is likely to be a peptide moiety.
Tissue plasminogen activators are proteases that are produced by polymorphonuclear leukocytes, macrophages, and embryonic tissues, as well as by a variety of transformed cells including cultured human meningiomas and malignant gliomas. 24'26'31'33 A number of differing molecular weight forms are known to exist (33, 54 to 60, 75, and 80 to 90 kD). The 75-kD molecular weight variety is unique in that it is produced exclusively by transformed cells and has been designated "tumor plasminogen activator" (TPA). It also appears to be antigenically distinct from normal tissuederived t-PA in that it is not inactivated by anti-urokinase immunoglobulin. A recent study by Quindlen and Buchet TM correlated human brain TPA activity in a fibrin-plate radial diffusion assay, with peritumoral brain edema on computerized tomography; however, the authors did not correlate the presence of this substance with activity in a standard assay for induction of microvascular permeability. In addition, in vivo t-PA toxicity studies in rats and rabbits failed to uncover any inflammatory, hemorrhagic, or edemagenic complications when this substance was used to facilitate aspiration of experimentally induced intracerebral hematomas. 13' 14.23 Conclusions regarding the actual relationship of this association to the mechanism of vasogenic brain edema formation in the setting of cerebral neoplasms would therefore be premature. We have found brain tumor-derived VPF activity to be resistant to the effects of protease inhibitors that normally inactivate leukokinins, serum, and tissue plasminogen. Furthermore, physical characteristics such as molecular weight, charge, and heparin affinity also distinguish VPF from a tissue or tumor plasminogen activator.
Incubation with dexamethasone inhibits expression of VPF by cultured human malignant glial cells. This effect is not explainable by cytotoxic effects or growth inhibition, nor does it correlate with cellular protein synthesis which is unaffected. Substantial inhibition of VPF activity in vivo occurs when test animals are treated with dexamethasone 2 hours prior to intraderreal injection of test substances. This protective effect is partially reversed by treatment of test animals with a protein synthesis inhibitor (actinomycin D) 2 hours prior to treatment with dexamethasone. Actinomycin D is known to inhibit deoxyribonucleic acid (DNA)-directed synthesis (transcription) of messenger RNA (mRNA). Our findings suggest that dexamethasone may exert its protective effect in vivo through a polypeptide intermediate requiring de novo synthesis upon exposure to glucocorticoid. This concept has been put forth as an explanation for the protective effect of dexamethasone in rats affected by global cerebral ischemia. 3~ Furthermore, a second messenger polypeptide (macrocortin), which mediates the effect of glucocorticoids by inhibition of phospholipase, has been characterized using rat peritoneal leukocytes and guinea pig lungs. 4 Induction of macrocortin synthesis was shown to require steroid receptor occupation and de novo protein synthesis.
In summary, a cationic polypeptide produced and released by cultured malignant astroglial tumors has been further characterized. This factor (VPF) is capable of inducing macromolecular extravasation (as demonstrated by J25I-BSA leakage) in a well-defined and predictable fashion when tested in the Miles microvascular permeability assay. Vascular permeability factor activity is avidly bound to immobilized heparin. This affinity is likely to be of biological importance in light of the ubiquitous presence of heparin-like moieties on endothelial cell surfaces and the inhibitory effects of heparin and protamine on VPF activity in vivo. These data provide some insight into the apparent clinical efficacy of dexamethasone in the setting of vasogenic brain edema associated with brain tumors. In addition, a variety of distinctions were made between brain tumorderived VPF and other known vascular permeability mediators.
